Moreover, our results obtained regarding NKG2D raise the possibility that other activating receptors and co-regulators such as DNAM-1, described to be involved in breast cancer-NK cell recognition [13], are involved in increasing trastuzumab activity in humans and await further investigation. This evidence concerns the gene CD226 and breast carcinoma.